
|Articles|March 1, 2001
- Pharmaceutical Executive-03-01-2001
- Volume 0
- Issue 0
Shortage: Vaccine Worries
Author(s)Andra Brichacek
United States-At this time last year, the United States} supply of tetanus vaccine was easily met by the two companies licensed to produce it there, Aventis Pasteur and Wyeth-Ayerst. But in June 2000, the latter ran into regulatory problems, and FDA seized thousands of substandard doses of acellular pertussis vaccine from the company}s Marietta, Pennsylvania, plant.
Advertisement
Articles in this issue
about 25 years ago
Research: New Horizonsabout 25 years ago
Earnings: Tough Times Aheadabout 25 years ago
Outbreak: Anthrax Alarmabout 25 years ago
Patents: China on the Genome Mapabout 25 years ago
Privacy, Pediatrics, and Policyabout 25 years ago
Lilly's International Familyabout 25 years ago
Update: Punishment and Reprieveabout 25 years ago
Gateway to Japanabout 25 years ago
SurroundedNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Asembia ASX26: Adjusting Strategies to Adapt to an Uncertain Global Political and Regulatory Market
2
Which Supply Chains are Most Exposed by Disruptions in The Strait of Hormuz?
3
Asembia AXS26 Summit: The Future of High-Cost Specialty Drugs
4
Pharmaceutical Executive Daily: FDA Approves Breztri
5




